Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Alzheimer Disease
A Drug With Efficacy Superior to That of Memantine Would Earn up to a 50% Patient Share in the Moderate-to-Severe Alzheimer's Disease Drug Market
March 21st, 2008
Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that a drug with efficacy superior to that of sales leader memantine would earn up to a 50% patient share in the market to treat moderate-to-severe Alzheimer's disease. The currently available branded versions of memantine are Forest Laboratories' Namenda, Lundbeck's Ebixa and Merz/Grupo Grunenthal's Axura/Akatinol. The new report entitled Alzheimer's Disease (Moderate to Severe): Incremental Improvements in Efficacy Can Lead to Large Commercial Opportunity finds that a symptomatic therapy with efficacy greater than that of memantine, as...
Source: Health Business Week (2008-03-21)
|
